Literature DB >> 34021704

A Potential Prophylactic Probiotic for Inflammatory Bowel Disease: The Overall Investigation of Clostridium tyrobutyricum ATCC25755 Attenuates LPS-Induced Inflammation via Regulating Intestinal Immune Cells.

Zhiping Xiao1, Lujie Liu1, Yuyue Jin1, Xun Pei1, Wanjing Sun1, Minqi Wang1.   

Abstract

SCOPE: This study aims to roundly investigate whether Clostridium tyrobutyricum (Ct) alleviates inflammation via regulating immune cells in the small intestines. METHODS AND
RESULTS: Mice are pre-treated with different concentrations of Ct follow by LPS stimulation. Ct maintains the mice body weight under inflammation. In response to LPS, 107 CFU mL-1 Ct decreases the mRNA expression of inflammatory cytokines in the duodenum, while 108 CFU mL-1 Ct reduces inflammatory cytokines expression in both duodenum and ileum and protected intestinal morphology. The small intestinal immune cells are analyzed using flow cytometry. Ct decreases the numbers of macrophages and mast cells in the intestines in response to LPS. In the duodenum, Ct enhances dentritic cells (DCs), regulatory T cells (Tregs), and T helper cell 17 (Th17) proportions. Ct decreases DCs and Tregs proportions, while enhances Th17 numbers in the ileum. The underlying mechanism of Ct in preventing inflammation may rely on the physiological immune cell composition of the intestines. In response to LPS, Ct may mainly stimulate Tregs via activating DCs in the duodenum while trigger Th17 cells in the ileum, thereby maintaining the intestinal homeostasis.
CONCLUSION: Ct alleviates the LPS-induce inflammation via regulating different immune cell types in the small intestines, highlighting that Ct is a potential prophylactic probiotic in intestinal diseases.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  Clostridium tyrobutyricum (Ct); immune cells; inflammatory bowel disease (IBD); intestine; probiotics

Mesh:

Substances:

Year:  2021        PMID: 34021704     DOI: 10.1002/mnfr.202001213

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  4 in total

1.  A Potential Probiotic for Diarrhea: Clostridium tyrobutyricum Protects Against LPS-Induced Epithelial Dysfunction via IL-22 Produced By Th17 Cells in the Ileum.

Authors:  Zhiping Xiao; Lujie Liu; Xun Pei; Wanjing Sun; Yuyue Jin; Shang-Tian Yang; Minqi Wang
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

2.  Functional Characterization of Clostridium tyrobutyricum L319: A Promising Next-Generation Probiotic for Short-Chain Fatty Acid Production.

Authors:  Zhihan Yang; Fatima Ezzahra Amal; Lei Yang; Yuxin Liu; Liying Zhu; Zhengming Zhu; Ling Jiang
Journal:  Front Microbiol       Date:  2022-06-17       Impact factor: 6.064

3.  Butyrate Glycerides Protect against Intestinal Inflammation and Barrier Dysfunction in Mice.

Authors:  Haidong Wang; Haohan Chen; Yueying Lin; Geng Wang; Yanqiu Luo; Xinyu Li; Minqi Wang; Mingyan Huai; Lily Li; Adriana Barri
Journal:  Nutrients       Date:  2022-09-26       Impact factor: 6.706

4.  In Situ Bioorthogonal Conjugation of Delivered Bacteria with Gut Inhabitants for Enhancing Probiotics Colonization.

Authors:  Wen-Fang Song; Wei-Qin Yao; Qi-Wen Chen; Diwei Zheng; Zi-Yi Han; Xian-Zheng Zhang
Journal:  ACS Cent Sci       Date:  2022-08-25       Impact factor: 18.728

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.